# US 2022/0041620 A1 · Kinase Inhibitors and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0041620 A1
- Document ID: US20220041620A1
- Status: Published application
- Kind: A1
- Application number: 17/511,193
- Filed: 2021-10-26
- Published: 2022-02-10
- Earliest claimed: 2017-05-17
- Assignees: Denali Therapeutics Inc.
- Applicants: Denali Therapeutics Inc.
- Inventors: Javier de Vicente Fidalgo; Anthony A. Estrada; Jianwen A. Feng; Brian Fox; Cinzia Maria Francini; Christopher R.H. Hale; Cheng Hu; Colin Philip Leslie; Maksim Osipov; Elena Serra; Zachary K. Sweeney; Arun Thottumkara
- Web page: https://patentgrep.com/patent/US20220041620A1

## CPC

- C07D 498/04: Ortho-condensed systems
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 223/16: Benzazepines; Hydrogenated benzazepines
- C07D 267/04: having the hetero atoms in positions 1 and 2
- C07D 267/14: condensed with one six-membered ring
- C07D 401/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.

## Claims

### Claim 1

A compound according to Formula I:
or a pharmaceutically acceptable salt, solvate, prodrug, isotopic analog, or isomer thereof, wherein
W1, W3, and W4 are CR7;
W2 is N or CR7;
provided that when W2 is CR7, then either
a) W4 is C—CN or
b) R1a is not hydrogen and R1b and R1c together form a piperidinyl ring substituted by (R5)n and n is 0-9;
R1a, R1b, and R1c are independently hydrogen, halogen, —CN, —N3, —NO2, —OH, —SF5, —SCF3, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 heteroalkyl, C3-8 cycloalkyl, C1-8 haloalkyl, C1-8 alkoxy, C1-8 haloalkoxy, 4- to 12-membered heterocyclyl, C6-10 aryl, 5- to 12-membered heteroaryl, —N(R1d)2, —C(O)R1e, —C(O)OR1d, —C(O)N(R1d)2, —NR1dC(O)R1e, —NR1dC(O)N(R1d)2,—NR1dC(O)OR1d, —OC(O)N(R1d)2, —OC(O)OR1d, —SR1d, —S(O)R1e, —S(O)2R1e, —S(O)3R1d, —S(O)N(R1d)2, —S(O)2N(R1d)2, —NR1dS(O)R1e, —NR1dS(O)2R1e, —NR1dS(O)N(R1d)2, or —NR1dS(O)2N(R1d)2, wherein each of R1a, R1b, and R1c is optionally and independently substituted with one to eight R5 and at least one of R1a, R1b, and R1c is other than hydrogen; or
R1b and R1c are optionally taken together to form C3-10 cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight R5; or
R1a, R1b, and R1c are optionally taken together to form C5-10 cycloalkyl or 6- to 8-membered heterocyclyl, each of which is optionally substituted with one to eight R5; or
R1a is absent and R1b and R1c are taken together to form C6-10 aryl or 5- to 12-membered heteroaryl, each of which is optionally substituted with one to eight R5;
each R1d is independently hydrogen, C1-8 alkyl, C1-8haloalkyl, C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl, or
two R1d on the same atom are optionally taken together to form a 4- to 8-membered heterocyclyl optionally substituted by oxo, halo, or C1-6 alkyl, wherein said alkyl is optionally substituted with one to eight R5;
each R1e is independently C1-8 alkyl, C1-8 haloalkyl, C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl;
R2a and R2b are independently hydrogen, halogen, C1-8 alkyl, C1-8 haloalkyl, C2-8 alkenyl, or C2-8 alkynyl, or
R2a and R2b are optionally taken together to form C3-6 cycloalkyl or 4- to 6-membered heterocyclyl, each of which is optionally substituted with one to eight R6;
R3a and R3b are independently hydrogen, halogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C3-6 cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R6, or
R3a and R3b are optionally taken together to form oxo, C3-6 cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R6;
Y is O, C(O), S, S(O), S(O)2, CR4aR4b, or NR4c;
R4a and R4b are independently hydrogen, halogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C3-6 cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R6, or
R4a and R4b are optionally taken together to form C3-6 cycloalkyl or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R6, or
R4a and R1b are optionally taken together to form 4- to 12-membered heterocyclyl, which is optionally substituted with one to eight R6, or
R4a and R3a are optionally taken together to form C3-8 cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight R6, or
R4c is hydrogen, C1-8 alkyl, C1-8 haloalkyl, C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl;
each R5 is independently halogen, —CN, —OH, —SF5, —SCF3, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 heteroalkyl, C3-8 cycloalkyl, C1-8 alkoxy, 4- to 12-membered heterocyclyl, C6-10 aryl, 5- to 12-membered heteroaryl, (4- to 12-membered heterocyclyl)(C1-8 heteroalkyl), (C6-10 aryl)(C1-8 heteroalkyl), (5- to 12-membered heteroaryl)(C1-8heteroalkyl), —N(R5a)2, —C(O)R5b, —C(O)OR5a, —C(O)N(R5a)2, —NR5aC(O)R5b, —NR5aC(O)N(R5a)2, —NR5aC(O)OR5a, —OC(O)N(R5a)2, —OC(O)OR5a, —SR5a, —S(O)R5b, —S(O)2R5b, —S(O)3R5a, —S(O)N(R5a)2, —S(O)2N(R5a)2, —NR5aS(O)R5b, —NR5aS(O)2R5b, —NR5aS(O)N(R5a)2, or —NR5aS(O)2N(R5a)2, each of which is optionally substituted with one to eight R5c, or
two R5 are optionally taken together to form oxo;
each R5a is independently hydrogen, C1-8 alkyl, C1-8 haloalkyl, C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl, and
each R5b is independently C1-8 alkyl, C1-8 haloalkyl, C3-10 cycloalkyl, 4- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl;
each R5c is independently halogen, cyano, C1-8 haloalkyl, C1-8 alkyl, C1-8 alkoxy, C1-8 haloalkoxy, (C1-8 alkoxy)(C1-8 alkoxy), hydroxyl, SR5d, N(R5d)2, N(R5d)2(C1-8 alkoxy), C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl, or
two R5c are optionally taken together to form oxo;
each R5d is independently hydrogen, C1-8 alkyl, or C1-8 haloalkyl;
each R6 is halogen, —CN, —OH, C1-8 alkyl, C1-8 heteroalkyl, C3-8 cycloalkyl, C1-8 haloalkyl, C1-8 alkoxy, 4- to 12-membered heterocyclyl, C6_o aryl, 5- to 12-membered heteroaryl, —N(R6a)2, —C(O)R6b, —C(O)N(R6a)2, or —C(O)OR6a, or
two R6 are taken together to form oxo;
each R6a is independently hydrogen, C1-8 alkyl, or C1-8 haloalkyl, or
two R6a on the same atom are optionally taken together to form 4- to 6-membered heterocyclyl;
each R6b is independently C1-8 alkyl or C1-8 haloalkyl;
each R7 is independently hydrogen, halogen, —CN, —N3, —NO2, —SF5, —SCF3, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 heteroalkyl, C3-8 cycloalkyl, C1-8 haloalkyl, 4- to 12-membered heterocyclyl, C6-10 aryl, 5- to 12-membered heteroaryl, —OR7a, —C(O)R7b, —N(R7a)2, —C(O)OR7a, —C(O)N(R7a)2, —NR7aC(O)R7b, —NR7aC(O)N(R7a)2,—NR7aC(O)OR7a, —OC(O)N(R7a)2, —OC(O)OR7a, —SR7a, —S(O)R7b, —S(O)2R7b, —S(O)3R7a, —S(O)N(R7a)2, —S(O)2N(R7a)2, —NR7aS(O)R7b, —NR7aS(O)2R7b, —NR7aS(O)N(R7a)2, or —NR7aS(O)2N(R7a)2, each of which is optionally and independently substituted with one to eight R8;
each R7a is independently hydrogen, C1-8 alkyl, C1-8 haloalkyl, C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl, or
two R7a on the same atom are optionally taken together to form a 4- to 8-membered heterocyclyl optionally substituted by oxo, halo, or C1-6 alkyl, wherein said alkyl is optionally substituted with one to eight R8;
each R7b is independently C1-8 alkyl, C1-8 haloalkyl, C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl;
each R8 is halogen, —CN, —OH, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 heteroalkyl, C3-8 cycloalkyl, C1-8 haloalkyl, C1-8 alkoxy, 4- to 12-membered heterocyclyl, C6-10 aryl, 5- to 12-membered heteroaryl, —N(R8a)2, —C(O)R5b, or —C(O)OR5a, or
two R8 are optionally taken together to form oxo;
each R8a is independently hydrogen, C1-8 alkyl, or C1-8 haloalkyl;
each R8b is independently C1-8 alkyl or C1-8 haloalkyl;
Z is C(R9)2, C(O), O, S, S(O), S(O)2, S(O)NR9, or NR9;
provided that when Z is N, then R3a and R3b are not oxo;
each R9 is independently hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C3-8 cycloalkyl, 4- to 8-membered heterocyclyl, or —C(O)R9a; and
R9a is C1-8 alkyl, C1-8 haloalkyl, C3-8 cycloalkyl, or 4- to 12-membered heterocyclyl, or
R9 and R3a are optionally taken together to form C3-8 cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight R6.

### Claim 2 (depends on 1)

A compound of claim 1, wherein W2 is N.

### Claim 3 (depends on 2)

A compound of claim 2, wherein
Z is O;
Y is CR4aR4b;
R2a, R2b, R3a, R3b, R4a, and R4b are H; and
R1a, R1b, R1c, R5, R7, and R8 are as defined for Formula I.

### Claim 4 (depends on 1)

A compound of claim 1, according to Formula Ia:
wherein
R1a, R2a, R2b, R3a, R3b, R5, R7, W1, W2, W3, W4, Y, and Z are as defined for Formula I; and
n is 0-9;
provided that when W1, W2, W3, and W4 are CR7, then R1a is not hydrogen.

### Claim 5 (depends on 4)

A compound of claim 4, wherein at least one of R5 is attached to the piperidine nitrogen atom.

### Claim 6 (depends on 1)

A compound of claim 1, according to Formula Ib:
wherein R1a, R1b, R1c, R2a, R2b, R3a, R3b, W1, W2, W3, Y, and Z are as defined for Formula I.

### Claim 7

A compound of any one of the preceding claims, wherein W2 is N and W1, W3, W4 are CR7.

### Claim 8

A compound of any one of the preceding claims, wherein W2 is N and W3 is CH.

### Claim 9

A compound of any one of the preceding claims, wherein W2 is N and each R7 is independently hydrogen, halogen, cyano, C1-8 alkyl, C1-8 haloalkyl, or C1-8 alkoxy.

### Claim 10

A compound of any one of the preceding claims, wherein W2 is CR7.

### Claim 11

A compound of any one of the preceding claims, wherein each R7 is independently hydrogen, halogen, cyano, C1-8 alkyl, C1-8 haloalkyl, or C1-8 alkoxy.

### Claim 12

A compound of any one of the preceding claims, wherein at least one R7 is halo, C1-6 alkyl, C1-6 alkoxy, or cyano.

### Claim 13

A compound of any one of the preceding claims, wherein at least one R7 is chloro, fluoro, methyl, methoxy, cyano, or bromo.

### Claim 14

A compound of any one of the preceding claims, wherein one or two of R7 is 7-chloro, 7-methyl, 8-methoxy, 9-fluoro, 6-fluoro, 6-fluoro-9-cyano, 7-fluoro-9-cyano, 9-cyano, 6-cyano, 8-cyano, 7-fluoro-, or 9-bromo-7-fluoro-.

### Claim 15

A compound of any one of the preceding claims, wherein W1 is CH, CF, or CCN.

### Claim 16

A compound of any one of the preceding claims, wherein W2 is CH, CCl, CF, or CCH3.

### Claim 17

A compound of any one of the preceding claims, wherein W3 is CH, COCH3, CCN, CF, CCl, or CCF3.

### Claim 18

A compound of any one of the preceding claims, wherein W4 is CH, CCN, CF, Br, Cl, CCl, or CCF3.

### Claim 19

A compound of any one of the preceding claims, wherein Z is CH2.

### Claim 20

A compound of any one of the preceding claims, wherein Z is O.

### Claim 21

A compound of any one of the preceding claims, wherein Y is CR4aR4b.

### Claim 22

A compound of any one of the preceding claims, wherein Y is O.

### Claim 23

A compound of any one of the preceding claims, wherein R1a is hydrogen, C1-8 alkyl, C1-8 haloalkyl, or C3-8 cycloalkyl, each of which is optionally substituted with halogen and —CN.

### Claim 24

A compound of any one of the preceding claims, wherein R1b and R1c are independently C1-8 alkyl, C1-8 haloalkyl, or C3-8 cycloalkyl, each of which is optionally substituted with halogen and —CN.

### Claim 25

A compound of any one of the preceding claims, wherein at least one of R1a, R1b, and R1c is chloro, methyl, —CD3, ethyl, difluoromethyl, cyanomethyl, cyclopropyl, cyclopropylmethyl, trifluoromethyl, methoxy, trifluoromethoxymethyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, 2-fluoroethyl, trifluoromethoxy, 1-cyanoethyl, fluoromethyl, 1-hydroxycyclopropyl, difluoromethylcyclopropyl, cyanocyclopropyl, 3,3-difluorocyclobutyl, 1,1,2,2,2-pentafluoroethyl, 1-methylethyl, methylsulfanyl, methoxymethyl, 5-fluoropyrimidin-2-ylsulfanyl, azetidin-3-yl, pyrroldin-3-yl, cyano, or hydroxyl.

### Claim 26

A compound of any one of the preceding claims, wherein R1b and R1c are taken together to form 4- to 12-membered heterocyclyl, which is optionally substituted with one to eight R5.

### Claim 27

A compound of any one of the preceding claims, wherein R1b and R1c are taken together to form a 4, 5, 6, or 7 membered heterocyclyl containing a nitrogen ring atom and optionally substituted with one to eight R5.

### Claim 28 (depends on 26, 27)

A compound of claim 26 or claim 27, wherein the heterocyclyl is substituted with one to four R5.

### Claim 29

A compound of any one of the preceding claims, wherein at least one of R5 is C1-8 alkyl, C1-8 haloalkyl, halogen, C1-8 haloalkyl, C1-8 alkoxy, —OH, or cyano.

### Claim 30

A compound of any one of the preceding claims, wherein at least one of R5 is methyl, ethyl, fluoro, chloro, difluoromethyl, fluoromethyl, methoxy, hydroxyl, C1-8 haloalkyl, halogen, C1-8 haloalkyl, C1-8 alkoxy, or cyano.

### Claim 31

A compound of any one of the preceding claims, wherein at least one of R5 is 4- to 12-membered heterocyclyl or 5- to 12-membered heteroaryl, each of which is optionally substituted with one to eight R5c.

### Claim 32 (depends on 31)

A compound of claim 31, wherein at least one of R5 is a 5- to 12-membered heteroaryl optionally substituted with one to eight R5c.

### Claim 33 (depends on 32)

A compound of claim 32, wherein the 5- to 12-membered heteroaryl is selected from pyrimidin-2-yl, pyrimidin-4-yl, pyrazin-2-yl, [1,2,4]triazolo[1,5-a]pyrazin-8-yl, triazolo[1,5-c]pyrimidin-5-yl, pyrazolo[1,5-a][1,3,5]triazin-4-yl, pyrazolo[1,5-a]pyrimidin-7-yl, pyridazin-4-yl, quinazolin-2-yl, imidazo[1,2-a]pyrazin-8-yl, pyrazolo[4,3-c]pyridin-6-yl, pyrrolo[3,2-d]pyrimidin-2-yl, imidazo[1,2-b]pyridazin-6-yl, pyrazolo[1,5-a]pyrimidin-7-yl, 6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl, pyrid-2-yl, pyrid-3-yl, methoxypyridazin-3-yl, 5,7-dihydrofuro[3,4-d]pyrimidin-2-yl, purin-2-yl, quinazolin-2-yl, quinoxalin-2-yl, isoquinol-3-yl, quinol-2-yl, and 1,3,5-triazin-2-yl, and imidazo[2,1-f][1,2,4]triazin-4-yl, each of which is optionally substituted with one to eight R5c.

### Claim 34 (depends on 32, 33)

A compound of claim 32 or 33, wherein the heterocyclyl is substituted with one to three R5c.

### Claim 35 (depends on 34)

A compound of claim 34, wherein R5, is independently fluoro, methoxy, difluoromethoxy, methyl, methylamino, cyclopropylamino, 2,2-difluoroethoxy, methylsulfanyl, dimethylaminopropoxy, chloro, 2-methoxyethoxy, dimethylaminoethoxy, cyano, trifluoromethyl, ethoxy, difluoromethyl, cyclopropyl, and oxo.

### Claim 36

A compound of any one of the preceding claims, wherein R1b and R1c are taken together to form 2,2-difluorocycobutyl, 3,3-difluorocycobutyl, (5-fluoropyrimidin-2-yl)piperidin-4-yl, tetrahydopyran-4-yl, tetrahydopyran-3-yl, tetrahydofuran-3-yl, cylcopropyl, or cyclobutyl.

### Claim 37

A compound of any one of the preceding claims, wherein R1a is hydrogen.

### Claim 38

A compound of any one of the preceding claims, wherein R1a is chloro, fluoro, methyl, ethyl, difluoromethyl, fluoromethyl, cyano, or hydroxyl.

### Claim 39

A compound of any one of the preceding claims, wherein R1a, R1b, and R1c are taken together to form bicyclo[1.1.1]pentane, azabicyclo[4.1.0]heptane, azepan-4yl, 1,4-oxepane-7-yl, tetrahydropyran-2-yl, or 3,6-dihydro-2H-pyridin-4-yl.

### Claim 40

A compound of any one of the preceding claims, wherein R2a is hydrogen and R2b is C1-8 alkyl.

### Claim 41

A compound of any one of the preceding claims, wherein R2a and R2b are hydrogen.

### Claim 42

A compound of any one of the preceding claims, wherein R4a is hydrogen or methyl.

### Claim 43

A compound of any one of the preceding claims, wherein R3a and R3b are independently hydrogen or methyl.

### Claim 44

A compound selected from Table 1 or Examples 258-309, or a pharmaceutically acceptable salt, solvate, prodrug, isotopic analog, or isomer thereof.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A pharmaceutical composition comprising a compound according to any one of claims 1-44, and a pharmaceutically acceptable excipient.

### Claim 46

A method for preparing a compound according to Formula A:
or a salt thereof, the method comprising:
contacting a compound according to Formula IIa
with a compound according to Formula IIb,
under conditions sufficient to form a compound according to Formula IIc
converting the compound of Formula IIc to a compound of Formula IId
and
contacting the compound of Formula IId with a compound of Formula IIe
under conditions sufficient to form the compound of Formula A;
wherein:
Z1 is an optionally protected first reactive group;
Z2 is an optionally protected second reactive group;
Q is —OH or a leaving group; and
W1, W2, W3, and W4 are independently N or CR7;
R1a, R1b, and R1c are independently hydrogen, halogen, —CN, —N3, —NO2, —OH, —SF5, —SCF3, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 heteroalkyl, C3-8 cycloalkyl, C1-8 haloalkyl, C1-8 alkoxy, C1-8 haloalkoxy, 4- to 12-membered heterocyclyl, C6-10 aryl, 5- to 12-membered heteroaryl, —N(R1d)2, —C(O)R1e, —C(O)OR1d, —C(O)N(R1d)2, —NR1dC(O)R1e, —NR1dC(O)N(R1d)2, —NR1dC(O)OR1d, —OC(O)N(R1d)2, —OC(O)OR1d, —SR1d, —S(O)R1e, —S(O)2R1e, —S(O)3R1d, —S(O)N(R1d)2, —S(O)2N(R1d)2, —NR1dS(O)R1e, —NR1dS(O)2R1e, —NR1dS(O)N(R1d)2, or —NR1dS(O)2N(R1d)2, wherein each of R1a, R1b, and R1c is optionally and independently substituted with one to eight R5 and at least one of R1a, R1b, and R1c is other than hydrogen; or
R1b and R1c are optionally taken together to form C3-10 cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight R5; or
R1a, R1b, and R1c are optionally taken together to form C5-10 cycloalkyl or 5- to 12-membered heterocyclyl, each which is optionally substituted with one to eight R5; or
R1a is absent and R1b and R1c are taken together to form C6-10 aryl or 5- to 12-membered heteroaryl or 5- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight R5;
each R1d is independently hydrogen, C1-8 alkyl, C1-8haloalkyl, C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl, or
two R1d on the same atom are optionally taken together to form a 4- to 8-membered heterocyclyl optionally substituted by oxo, halo, or C1-6 alkyl, wherein said alkyl is optionally substituted with one to eight R5;
each R1e is independently C1-8 alkyl, C1-8 haloalkyl, C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl;
R2a and R2b are independently hydrogen, halogen, C1-8 alkyl, C1-8haloalkyl, C2-8 alkenyl, or C2-8 alkynyl, or
R2a and R2b are optionally taken together to form C3-6 cycloalkyl or 4- to 6-membered heterocyclyl, each of which is optionally substituted with one to eight R6;
R3a and R3b are independently hydrogen, halogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C3-6 cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R6, or
R3a and R3b are optionally taken together to form oxo, C3-6 cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R6;
Y is O, C(O), S, S(O), S(O)2, CR4aR4b, or NR4c;
R4a and R4b are independently hydrogen, halogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C3-6 cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R6, or
R4a and R4b are optionally taken together to form C3-6 cycloalkyl or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R6, or
R4a and R1b are optionally taken together to form 4- to 12-membered heterocyclyl, which is optionally substituted with one to eight R6, or
R4a and R3a are optionally taken together to form C3-8 cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight R6, or
R4c is hydrogen, C1-8 alkyl, C1-8 haloalkyl, C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl;
each R5 is independently halogen, —CN, —OH, —SF5, —SCF3, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C1-8 heteroalkyl, C3-8 cycloalkyl, C1-8 haloalkyl, C1-8 alkoxy, C1-8 haloalkoxy, 4- to 12-membered heterocyclyl, C6-10 aryl, 5- to 12-membered heteroaryl, (4- to 12-membered heterocyclyl)(C1-8 heteroalkyl), (C6-10 aryl)(C1-8 heteroalkyl), (5- to 12-membered heteroaryl)(C1-8 heteroalkyl), —N(R5a)2, —C(O)R5b, —C(O)OR5a, —C(O)N(R5a)2, —NR5aC(O)R5b, —NR5aC(O)N(R5a)2, —NR5aC(O)OR5a, —OC(O)N(R5a)2, —OC(O)OR5a, —SR5a, —S(O)R5b, —S(O)2R5b, —S(O)3R5a, —S(O)N(R5a)2, —S(O)2N(R5a)2, —NR5aS(O)R5b, —NR5aS(O)2R5b, —NR5aS(O)N(R5a)2, or —NR5aS(O)2N(R5a)2, each of which is optionally substituted with one to eight R5c, or
two R5 are optionally taken together to form oxo;
each R5a is independently hydrogen, C1-8 alkyl, C1-8 haloalkyl, C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl, and
each R5b is independently C1-8 alkyl, C1-8 haloalkyl, C3-10 cycloalkyl, 4- to 12-membered heterocyclyl, or 5- to 12-membered heteroaryl;
each R5, is independently halogen, cyano, C1-8 haloalkyl, C1-8 alkyl, C1-8 alkoxy, C1-8 haloalkoxy, (C1-8 alkoxy)(C1-8 alkoxy), hydroxyl, SR5d, N(R5d)2, N(R5d)2(C1-8 alkoxy), C3-10 cycloalkyl, and 4- to 12-membered heterocyclyl, or two R5c are optionally taken together to form oxo;
each R5d is independently hydrogen, C1-8 alkyl, or C1-8 haloalkyl;
each R6 is halogen, —CN, —OH, C1-8 alkyl, C1-8 heteroalkyl, C3-8 cycloalkyl, C1-8 haloalkyl, C1-8 alkoxy, 4- to 12-membered heterocyclyl, C6-10 aryl, 5- to 12-membered heteroaryl, —N(R6a)2, —C(O)R6b, —C(O)N(R6a)2, or —C(O)OR6a, or
two R6 are taken together to form oxo;
each R6a is independently hydrogen, C1-8 alkyl, or C1-8 haloalkyl, or
two R6a on the same atom are optionally taken together to form 4- to 6-membered heterocyclyl;
each R6b is independently C1-8 alkyl or C1-8 haloalkyl;
each R7 is independently hydrogen, halogen, —CN, —N3, —NO2, —SF5, —SCF3, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 heteroalkyl, C3-8 cycloalkyl, C1-8 haloalkyl, 4- to 12-membered heterocyclyl, C6-10 aryl, 5- to 12-membered heteroaryl, —OR7a, —C(O)R7b, —N(R7a)2, —C(O)OR7a, —C(O)N(R7a)2, —NR7aC(O)R7b, —NR7aC(O)N(R7a)2,—NR7aC(O)OR7a, —OC(O)N(R7a)2, —OC(O)OR7a, —SR7a, —S(O)R7b, —S(O)2R7b, —S(O)3R7a, —S(O)N(R7a)2, —S(O)2N(R7a)2, —NR7aS(O)R7b, —NR7aS(O)2R7b, —NR7aS(O)N(R7a)2, or —NR7aS(O)2N(R7a)2, each of which is optionally and independently substituted with one to eight R8;
each R7a is independently hydrogen, C1-8 alkyl, C1-8 haloalkyl, C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl, or
two R7a on the same atom are optionally taken together to form a 4- to 8-membered heterocyclyl optionally substituted by oxo, halo, or C1-6 alkyl, wherein said alkyl is optionally substituted with one to eight R8;
each R7b is independently C1-8 alkyl, C1-8 haloalkyl, C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl;
each R8 is halogen, —CN, —OH, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 heteroalkyl, C3-8 cycloalkyl, C1-8 haloalkyl, C1-8 alkoxy, 4- to 12-membered heterocyclyl, C6-10 aryl, 5- to 12-membered heteroaryl, —N(R8a)2, —C(O)R5b, or —C(O)OR5a, or two R8 are optionally taken together to form oxo;
each R8a is independently hydrogen, C1-8 alkyl, or C1-8 haloalkyl;
each R8b is independently C1-8 alkyl or C1-8 haloalkyl;
Z is C(R9)2, C(O), O, S, S(O), S(O)2, S(O)NR9, or NR9;
each R9 is independently hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C3-8 cycloalkyl, 4- to 8-membered heterocyclyl, or —C(O)R9a; and
R9a is C1-8 alkyl, C1-8 haloalkyl, C3-8 cycloalkyl, or 4- to 12-membered heterocyclyl, or
R9 and R3a are optionally taken together to form C3-8 cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight R6.

### Claim 47

A compound according to Formula IId,
or a salt thereof, wherein
W1, W2, W3, and W4 are independently N or CR7;
R2a and R2b are independently hydrogen, halogen, C1-8 alkyl, C1-8 haloalkyl, C2-8 alkenyl, or C2-8 alkynyl, or
R2a and R2b are optionally taken together to form C3-6 cycloalkyl or 4- to 6-membered heterocyclyl, each of which is optionally substituted with one to eight R6;
R3a and R3b are independently hydrogen, halogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C3-6 cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R6, or
R3a and R3b are optionally taken together to form oxo, C3-6 cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R6;
Y is O, C(O), S, S(O), S(O)2, CR4aR4b, or NR4c;
R4a and R4b are independently hydrogen, halogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C3-6 cycloalkyl, or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R6, or
R4a and R4b are optionally taken together to form C3-6 cycloalkyl or 4- to 6-membered heterocyclyl, wherein said cycloalkyl and said heterocyclyl are optionally substituted with one to eight R6, or
R4a and R1b are optionally taken together to form 4- to 12-membered heterocyclyl, which is optionally substituted with one to eight R6, or
R4a and R3a are optionally taken together to form C3-8 cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight R6, or
R4c is hydrogen, C1-8 alkyl, C1-8 haloalkyl, C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl;
each R6 is halogen, —CN, —OH, C1-8 alkyl, C1-8 heteroalkyl, C3-8 cycloalkyl, C1-8 haloalkyl, C1-8 alkoxy, 4- to 12-membered heterocyclyl, C6_o aryl, 5- to 12-membered heteroaryl, —N(R6a)2, —C(O)R6b, —C(O)N(R6a)2, or —C(O)OR6a, or
two R6 are taken together to form oxo;
each R6a is independently hydrogen, C1-8 alkyl, or C1-8 haloalkyl, or
two R6a on the same atom are optionally taken together to form 4- to 6-membered heterocyclyl;
each R6b is independently C1-8 alkyl or C1-8 haloalkyl;
each R7 is independently hydrogen, halogen, —CN, —N3, —NO2, —SF5, —SCF3, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 heteroalkyl, C3-8 cycloalkyl, C1-8 haloalkyl, 4- to 12-membered heterocyclyl, C6-10 aryl, 5- to 12-membered heteroaryl, —OR7a, —C(O)R7b, —N(R7a)2, —C(O)OR7a, —C(O)N(R7a)2, —NR7aC(O)R7b, —NR7aC(O)N(R7a)2,—NR7aC(O)OR7a, —OC(O)N(R7a)2, —OC(O)OR7a, —SR7a, —S(O)R7b, —S(O)2R7b, —S(O)3R7a, —S(O)N(R7a)2, —S(O)2N(R7a)2, —NR7aS(O)R7b, —NR7aS(O)2R7b, —NR7aS(O)N(R7a)2, or —NR7aS(O)2N(R7a)2, each of which is optionally and independently substituted with one to eight R8;
each R7a is independently hydrogen, C1-8 alkyl, C1-8 haloalkyl, C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl, or
two R7a on the same atom are optionally taken together to form a 4- to 8-membered heterocyclyl optionally substituted by oxo, halo, or C1-6 alkyl, wherein said alkyl is optionally substituted with one to eight R8;
each R7b is independently C1-8 alkyl, C1-8 haloalkyl, C3-10 cycloalkyl, or 4- to 12-membered heterocyclyl;
each R8 is halogen, —CN, —OH, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 heteroalkyl, C3-8 cycloalkyl, C1-8 haloalkyl, C1-8 alkoxy, 4- to 12-membered heterocyclyl, C6-10 aryl, 5- to 12-membered heteroaryl, —N(R8a)2, —C(O)R5b, or —C(O)OR5a, or
two R8 are optionally taken together to form oxo;
each R8a is independently hydrogen, C1-8 alkyl, or C1-8 haloalkyl;
each R8b is independently C1-8 alkyl or C1-8 haloalkyl;
Z is C(R9)2, C(O), O, S, S(O), S(O)2, S(O)NR9, or NR9;
each R9 is independently hydrogen, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-8 haloalkyl, C3-8 cycloalkyl, 4- to 8-membered heterocyclyl, or —C(O)R9a; and
R9a is C1-8 alkyl, C1-8 haloalkyl, C3-8 cycloalkyl, or 4- to 12-membered heterocyclyl, or
R9 and R3a are optionally taken together to form C3-8 cycloalkyl or 4- to 12-membered heterocyclyl, each of which is optionally substituted with one to eight R6.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A method of inhibiting receptor-interacting protein kinase 1, the method comprising contacting the receptor-interacting protein kinase 1 with an effective amount of a compound according to any one of claims 1-44.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method of treating a receptor-interacting protein kinase 1-mediated disease or disorder comprising administering a therapeutically effective amount of a compound according to any one of claims 1-44 or a pharmaceutical composition according to claim 45 to a subject in need thereof.

### Claim 50 (depends on 49)

The method of claim 49, wherein the receptor-interacting protein kinase 1-mediated disease or disorder is necrotizing enterocolitis, tuberous sclerosis, Tangier's Disease, Wohlman's Syndrome, inflammatory bowel disease, Crohn's disease, ulcerative colitis, psoriasis, retinal detachment, retinitis pigmentosa, macular degeneration, pancreatitis (e.g., acute pancreatitis), atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, gout, SoJIA, systemic lupus erythematosus, Sjogren's syndrome, systemic scleroderma, anti-phospholipid syndrome, vasculitis, osteoarthritis, non-alcohol steatohepatitis, alcohol steatohepatitis, autoimmune hepatitis autoimmune hepatobiliary diseases, primary sclerosing cholangitis, nephritis, Celiac disease, autoimmune ITP, transplant rejection, ischemia, ischemia reperfusion injury of solid organs, cerebral ischemia, sepsis, systemic inflammatory response syndrome, cerebrovascular accident, myocardial infarction, Huntington's disease, Alzheimer's disease, Parkinson's disease, allergic diseases, asthma, atopic dermatitis, multiple sclerosis, type I diabetes, Wegener's granulomatosis, pulmonary sarcoidosis, Behçet's disease, interleukin-1 converting enzyme associated fever syndrome, chronic obstructive pulmonary disease, tumor necrosis factor receptor-associated periodic syndrome, periodontitis, infection, bacterial infection, staphylococcus infection, mycobacterium infection, influenza, transplant rejection, burns, hypoxia, trauma, stroke, cardiac infarction, lysosomal storage disease, Niemann-Pick disease, Gaucher's disease, Krabbe disease, amyotrophic lateral sclerosis (ALS/Lou Gehrig's Disease), HIV-associated dementia, encephalopathy, retinal degenerative disease, glaucoma, age-related macular degeneration, Friedreich's ataxia, Lewy body disease, diabetic neuropathy, polyglutamine (polyQ) diseases, Fahr disease, Menke's disease, Wilson's disease, a prion disorder, atherosclerosis, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, major depressive disorder, bipolar disorder, delirium, post-operative cognitive impairment, autism, schizophrenia, or hidradenitis suppurativa.
